Archive: Company News
Company News: Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine
— The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability
— Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible
Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study of the second-generation COP allergy vaccines based on its research collaboration with Mymetics SA, a leader in the research and development of virosome-based vaccines. Read more…
Company News: Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for the Treatment of Chronic Heart Failure
— Collaboration with Hannover Medical School (MHH)
Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH). Read more…
Company News: BellaSeno Receives RegMedNet Award for Cultivating Excellence
– Leipzig-based start-up prepares for first clinical trial in 2019
BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technology , today announced it was awarded the 2018 Award for Cultivating Excellence by RegMedNet for its innovation, creativity, professionalism and investment in young professionals. BellaSeno won the public vote after five finalists were shortlisted by an expert jury. The award was established in 2017 to increase the visibility of the most valuable players in regenerative medicine.
Company News: Curetis Announces Financial Results for the First Nine Months of 2018
– Total year-on-year revenue growth of 43% globally, 207% in EMEA direct selling markets
– Initial traction in U.S. market after Unyvero launch
– Strategic collaboration with BCB in Greater China expanded
– Commercial reach expanded to Northern Africa, South America and Asia
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first nine months ended September 30, 2018, and provided a business update for the third quarter of 2018. Read more…